BR9812139A - Vacina - Google Patents

Vacina

Info

Publication number
BR9812139A
BR9812139A BR9812139-1A BR9812139A BR9812139A BR 9812139 A BR9812139 A BR 9812139A BR 9812139 A BR9812139 A BR 9812139A BR 9812139 A BR9812139 A BR 9812139A
Authority
BR
Brazil
Prior art keywords
hpv
vaccine
provides
prophylaxis
linked
Prior art date
Application number
BR9812139-1A
Other languages
English (en)
Inventor
Claudine Bruck
Teresa Cabezon Silva
Anne-Marie Eva Fernand Delisse
Catherine Marie Ghislai Gerard
Angela Lombardo-Bencheikh
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of BR9812139A publication Critical patent/BR9812139A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção:<B>"VACINA"<D>. A patente de invenção proporciona proteínas de fusão do vírus do papiloma humano (HPV), ligadas a um parceiro de fusão imunológica que proporciona epítopos T auxiliares ao antígeno de HPV. São providas formulações de vacina que são úteis no tratamento ou profilaxia de lesões induzidas por HPV.
BR9812139-1A 1997-08-22 1998-08-17 Vacina BR9812139A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9717953.5A GB9717953D0 (en) 1997-08-22 1997-08-22 Vaccine
PCT/EP1998/005285 WO1999010375A2 (en) 1997-08-22 1998-08-17 Vaccine against hpv

Publications (1)

Publication Number Publication Date
BR9812139A true BR9812139A (pt) 2000-07-18

Family

ID=10817971

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812139-1A BR9812139A (pt) 1997-08-22 1998-08-17 Vacina

Country Status (23)

Country Link
US (2) US6342224B1 (pt)
EP (1) EP1007551B1 (pt)
JP (1) JP2001513986A (pt)
KR (1) KR20010023193A (pt)
CN (1) CN1276833A (pt)
AT (1) ATE267211T1 (pt)
AU (1) AU732946B2 (pt)
BR (1) BR9812139A (pt)
CA (1) CA2301920C (pt)
CO (1) CO4810234A1 (pt)
DE (1) DE69824013T2 (pt)
ES (1) ES2221198T3 (pt)
GB (1) GB9717953D0 (pt)
HU (1) HUP0004327A3 (pt)
IL (1) IL134392A0 (pt)
MA (1) MA24638A1 (pt)
NO (1) NO20000850L (pt)
NZ (1) NZ502632A (pt)
PL (1) PL339009A1 (pt)
TR (1) TR200000480T2 (pt)
UY (1) UY25146A1 (pt)
WO (1) WO1999010375A2 (pt)
ZA (1) ZA987591B (pt)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
JP4303418B2 (ja) * 1997-10-24 2009-07-29 ライフ テクノロジーズ コーポレーション 組換え部位を有する核酸を使用する組換えクローニング
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
SI1117421T1 (en) * 1998-10-05 2004-12-31 Pharamexa A/S Methods for therapeutic vaccination
EA003634B1 (ru) 1998-10-05 2003-08-28 Фармэкса А/С Новые способы терапевтической вакцинации
DE69935606T9 (de) * 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
TR200103266T2 (tr) * 1999-05-13 2002-01-21 American Cyanamid Company Yardımcı kombinasyon formülasyonları
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7015033B1 (en) 2000-05-25 2006-03-21 Aventis Pasteur Limited Co-expression of recombination proteins
CA2412084A1 (en) * 2000-06-26 2002-01-03 Glaxosmithkline Biologicals S.A. Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
ES2284559T3 (es) * 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.
AU2002340662B2 (en) * 2001-11-07 2008-07-03 Tekmira Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
FR2839072A1 (fr) * 2002-04-24 2003-10-31 Neovacs Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
FR2839080B1 (fr) * 2003-04-03 2007-09-28 Neovacs Procede de preparation d'un produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, par des cellules de la levure pichia pastoris
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
WO2004009768A2 (en) * 2002-07-18 2004-01-29 Invitrogen Corporation Viral vectors containing recombination sites
KR101239242B1 (ko) 2002-08-02 2013-03-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 조합물을 포함하는 나이세리아 백신 조성물
WO2004019974A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
KR101145190B1 (ko) * 2002-10-03 2012-05-14 와이어쓰 홀딩스 코포레이션 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물
ES2649048T3 (es) 2002-11-01 2018-01-09 Glaxosmithkline Biologicals S.A. Procedimiento de secado
CN100443116C (zh) * 2002-11-07 2008-12-17 新纳几美国公司 治疗或预防肺炎球菌感染的组合物及其用途
CN100506999C (zh) * 2003-03-24 2009-07-01 麦克公司 Hpv31l1在酵母中的优化表达
CZ297389B6 (cs) * 2003-07-03 2006-11-15 Ústav Molekulární Biologie Rostlin Av Cr Fúzní protein pro vakcinaci proti lidskému papillomaviru a zpusob jeho produkce
WO2005032584A2 (en) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
EP1697534B1 (en) * 2003-12-01 2010-06-02 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US20070014810A1 (en) * 2003-12-31 2007-01-18 Denise Baker Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
CN1950483A (zh) * 2004-04-28 2007-04-18 上游重油有限公司 固定床加氢处理法和***，以及用来升级已有固定床***的方法
US10941353B2 (en) * 2004-04-28 2021-03-09 Hydrocarbon Technology & Innovation, Llc Methods and mixing systems for introducing catalyst precursor into heavy oil feedstock
EP2811006A1 (en) * 2004-04-28 2014-12-10 Headwaters Heavy Oil, LLC Ebullated bed hydroprocessing methods and systems and methods of upgrading an existing ebullated bed system
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN105063064A (zh) 2006-07-28 2015-11-18 宾夕法尼亚大学托管会 改进的疫苗及其使用方法
TW200821026A (en) * 2006-09-08 2008-05-16 Wyeth Corp Arginine wash in protein purification using affinity chromatography
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
EP2086582B1 (en) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
US20100003704A1 (en) 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
WO2010129821A1 (en) 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
AU2008207025B2 (en) * 2007-01-15 2012-08-23 Glaxosmithkline Biologicals Sa Vaccine
US8034232B2 (en) * 2007-10-31 2011-10-11 Headwaters Technology Innovation, Llc Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
TWI376385B (en) 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8142645B2 (en) * 2008-01-03 2012-03-27 Headwaters Technology Innovation, Llc Process for increasing the mono-aromatic content of polynuclear-aromatic-containing feedstocks
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
CA2653478A1 (en) 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
TWI409275B (zh) * 2009-06-22 2013-09-21 Nat Health Research Institutes 脂質化腫瘤相關抗原及其免疫治療的組成物及方法
KR20130127547A (ko) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
WO2011084598A1 (en) 2010-01-08 2011-07-14 Oncohealth Corporation High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
CN103180343B (zh) * 2010-08-13 2016-01-20 株式会社吉耐森 用于预防或治疗***的、包含人***瘤病毒变形体及免疫增强剂的组合物
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
US9790440B2 (en) 2011-09-23 2017-10-17 Headwaters Technology Innovation Group, Inc. Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
ES2646590T3 (es) * 2012-01-24 2017-12-14 Sanford Health Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
EP3388835B1 (en) 2012-05-16 2020-04-01 Immune Design Corp. Vaccines for hsv-2
US9644157B2 (en) 2012-07-30 2017-05-09 Headwaters Heavy Oil, Llc Methods and systems for upgrading heavy oil using catalytic hydrocracking and thermal coking
EA034056B1 (ru) 2013-03-12 2019-12-23 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Усовершенствованные вакцины против вируса папилломы человека и способы их применения
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US11801223B2 (en) 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
CN103772508B (zh) * 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人***瘤病毒感染及相关疾病的治疗性疫苗
CN107073070A (zh) 2014-08-15 2017-08-18 格纳西尼有限公司 治疗***的方法
CN107075491B (zh) * 2014-10-28 2021-07-06 谷万达公司 用于稳定反式剪接的内含肽修饰的蛋白酶的方法和组合物
WO2016090540A1 (zh) * 2014-12-08 2016-06-16 刘日廷 人***瘤病毒(hpv)18型致癌性e6和e7蛋白的抗原表位最小基序肽
JP5973007B2 (ja) * 2015-01-30 2016-08-17 ジェネクサイン・インコーポレーテッド ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
US11414607B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor with increased production rate of converted products
US11414608B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor used with opportunity feedstocks
TWI670280B (zh) * 2016-02-23 2019-09-01 財團法人國家衛生研究院 人類乳突病毒之脂質抗原及用於人類乳突病毒相關疾病之免疫治療組合物
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
US11421164B2 (en) 2016-06-08 2022-08-23 Hydrocarbon Technology & Innovation, Llc Dual catalyst system for ebullated bed upgrading to produce improved quality vacuum residue product
US11732203B2 (en) 2017-03-02 2023-08-22 Hydrocarbon Technology & Innovation, Llc Ebullated bed reactor upgraded to produce sediment that causes less equipment fouling
MX2018002577A (es) 2017-03-02 2018-11-09 Hydrocarbon Tech & Innovation Llc Reactor de lecho en ebullicion mejorado con menos sedimento de ensuciamiento.
WO2018232257A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
CA3057131C (en) 2018-10-17 2024-04-23 Hydrocarbon Technology And Innovation, Llc Upgraded ebullated bed reactor with no recycle buildup of asphaltenes in vacuum bottoms
PE20231054A1 (es) 2020-04-24 2023-07-11 Genexine Inc Metodo para tratamiento del cancer cervicouterino

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586428B1 (fr) 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
DE3907721A1 (de) 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
DE4015044A1 (de) 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
WO1992005248A1 (en) 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
DE4441197C1 (de) * 1994-11-18 1996-03-28 Deutsches Krebsforsch Expressionsplasmide für Hefe
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US5843752A (en) 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US5958750A (en) * 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase

Also Published As

Publication number Publication date
ATE267211T1 (de) 2004-06-15
WO1999010375A2 (en) 1999-03-04
US6342224B1 (en) 2002-01-29
IL134392A0 (en) 2001-04-30
NO20000850D0 (no) 2000-02-21
MA24638A1 (fr) 1999-04-01
NO20000850L (no) 2000-04-14
CA2301920A1 (en) 1999-03-04
CA2301920C (en) 2011-01-04
GB9717953D0 (en) 1997-10-29
DE69824013D1 (de) 2004-06-24
TR200000480T2 (tr) 2000-07-21
NZ502632A (en) 2002-03-28
DE69824013T2 (de) 2005-06-02
AU732946B2 (en) 2001-05-03
HUP0004327A3 (en) 2003-08-28
CO4810234A1 (es) 1999-06-30
CN1276833A (zh) 2000-12-13
PL339009A1 (en) 2000-12-04
UY25146A1 (es) 2000-12-29
US20020182221A1 (en) 2002-12-05
ES2221198T3 (es) 2004-12-16
ZA987591B (en) 2000-02-21
KR20010023193A (ko) 2001-03-26
EP1007551B1 (en) 2004-05-19
JP2001513986A (ja) 2001-09-11
EP1007551A2 (en) 2000-06-14
WO1999010375A3 (en) 1999-06-10
HUP0004327A1 (en) 2001-03-28
AU9263998A (en) 1999-03-16

Similar Documents

Publication Publication Date Title
BR9812139A (pt) Vacina
BR9814487A (pt) &#34;vacina&#34;
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
HUP0301308A2 (hu) Emberi Papillomavírus-fertőzés gyógykezelése
IL134341A0 (en) Compositions for inducing an immune response containing an hpv protein antigen
DE69936784D1 (de) Behandlung von gebärmutterhalskrebs
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
HK1037639A1 (en) Particles of hcv envelope proteins: use for vaccination hcv.
UA85536C2 (en) Viral antigens
DE69840383D1 (de) Ctl epitope des epstein-barr virus
ATE340859T1 (de) Rekombinantes papillomavirus l1 protein
CY1108106T1 (el) Χειμερικα μορια l1 ανθρωπινου θηλωματοϊου (hpv) και χρησεις τους
WO2002068654A3 (es) Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana
CA2295316A1 (en) Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
WO2002070004A3 (en) Papillomavirus vaccines
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
ECSP982629A (es) Proteinas de fusion, proteina que proporciona epitopos auxiliares de t un antigeno de virus de papiloma humano
AP1638A (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them.
ES2105984A1 (es) Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
RU2001127050A (ru) Штамм вируса Эбола &#34;Заир К-5&#34; для проведения модельных экспериментов и приготовления диагностических и вакцинных препаратов

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.